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speed at which drug leads can be identified and evalu-
ated in silico.
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combinatorial chemistry and structure-based design
can lead to the parallel synthesis of focused compound
libraries. It is also important to consider that structure-
based drug design directs the discovery of a drug lead,Summary
which is not a drug product but, specifically, a com-
pound with at least micromolar affinity for a target [10].The field of structure-based drug design is a rapidly
growing area in which many successes have occurred The time devoted to the structure-based drug design
process, as outlined in this review, may represent only ain recent years. The explosion of genomic, proteomic,
and structural information has provided hundreds of fraction of the total time toward developing a marketable
drug product. Many years of research may be necessarynew targets and opportunities for future drug lead
discovery. This review summarizes the process of to convert a drug lead into a drug that will be both
effective and tolerated by the human body. Additionalstructure-based drug design and includes, primarily,
the choice of a target, the evaluation of a structure of years of research and development will bring the drug
through clinical trials to finally reach the market.that target, the pivotal questions to consider in choos-
ing a method for drug lead discovery, and evaluation This review is intended to provide an overview of the
process of structure-based drug design from the selec-of the drug leads. Key principles in the field of struc-
ture-based drug design will be illustrated through a tion of a target to the generation and evaluation of lead
compounds. An in-depth discussion or evaluation of thecase study that explores drug design for AmpC
-lactamase. computational methods involved in drug discovery will
not be provided here, since that subject has been cov-
ered in reviews elsewhere [11–17].Introduction
During the early 1980s, the ability to rationally design
drugs using protein structures was an unrealized goal Overview of the Process
for many structural biologists. The first projects were The process of structure-based drug design is an itera-
underway in the mid-80s, and by the early 1990s the tive one (see Figure 1) and often proceeds through multi-
first success stories were published [1–3]. Today, even ple cycles before an optimized lead goes into phase I
though there is still quite a bit of fine-tuning necessary clinical trials. The first cycle includes the cloning, purifi-
to perfect the process, structure-based drug design is cation and structure determination of the target protein
an integral part of most industrial drug discovery pro- or nucleic acid by one of three principal methods: X-ray
grams [4] and is the major subject of research for many crystallography, NMR, or homology modeling. Using
academic laboratories. computer algorithms, compounds or fragments of com-
The completion of the human genome project, the pounds from a database are positioned into a selected
start of both the proteomics and structural genomics region of the structure. These compounds are scored
revolutions, and developments in information technol- and ranked based on their steric and electrostatic inter-
ogy are fueling an even greater opportunity for structure- actions with the target site, and the best compounds
based drug design to be part of the success story in are tested with biochemical assays. In the second cycle,
the discovery of new drug leads. Excellent drug targets structure determination of the target in complex with a
are identified at an increased pace using developments promising lead from the first cycle, one with at least
in bioinformatics. The genes for these targets can be micromolar inhibition in vitro, reveals sites on the com-
cloned quickly, and the protein expressed and purified pound that can be optimized to increase potency. Addi-
to homogeneity. Advances in high-throughput crystal- tional cycles include synthesis of the optimized lead,
lography, such as automation at all stages, more intense structure determination of the new target:lead complex,
synchrotron radiation, and new developments in phase and further optimization of the lead compound. After
determination, have shortened the timeline for determin- several cycles of the drug design process, the optimized
ing structures. Structure determination using nuclear compounds usually show marked improvement in bind-
magnetic resonance (NMR) has also seen a number of ing and, often, specificity for the target.
advances in the past years, including magnet and probe
improvements, automated assignment [5–7], and new
Choice of a Drug Targetexperimental methods to determine larger structures
The choice of a drug target is primarily made on a biolog-[8]. Faster computers and the availability of relatively
ical and biochemical basis. The ideal target macromole-inexpensive clusters of computers have increased the
cule for structure-based drug design is one that is
closely linked to human disease and binds a small mole-
cule in order to carry out a function. The target molecule*Correspondence: amy.c.anderson@dartmouth.edu
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Figure 1. The Iterative Process of Structure-
Based Drug Design
usually has a well-defined binding pocket. Other de- small molecule. The target should be essential, in that
it is part of a crucial cycle in the cell, and its eliminationsigned small molecules can compete, at a required level
of potency, with the natural small molecule in order to should lead to the pathogen’s death. The target should
be unique: no other pathway should be able to supple-modulate the function of the target. Many good drug
targets are proteins; however, drug design against RNA ment the function of the target and overcome the pres-
ence of the inhibitor. If the macromolecule satisfies alltargets with well-defined secondary structure, like the
bacterial ribosome and portions of the HIV genome, has outlined criteria to be a drug target but functions in
healthy human cells as well as in a pathogen, specificityalso been effective. Recent reviews highlight some of
the RNA structure-based projects underway [18, 19]. In can often be engineered into the inhibitor by exploiting
structural or biochemical differences between thediseases caused by the malfunction of human proteins,
small molecule drugs against G protein coupled recep- pathogenic and human forms. Finally, the target mole-
cule should be able to be inhibited by binding a smalltors (GPCRs) represent at least 25% of the currently
marketed drugs [20]. Small molecules that modulate molecule. Enzymes are often excellent drug targets be-
cause compounds can be designed to fit within thethe function of ion channels, proteases, kinases, and
nuclear hormone receptors make up another 22% of the active site pocket.
Cancer targets can be difficult because the targetsmarket.
The goal in developing drugs against the targets listed are often somatic cell mutants of proteins that regulate
essential cellular functions, resulting in the loss of aabove is often to modulate the function of the human
protein; the goal in developing drugs against pathogenic function. Of course, it is difficult for a small molecule
to potentiate the recovery of a function. However, asorganisms is total inhibition, leading to the death of the
pathogen. Antimicrobial drug targets should be essen- pointed out in a perspective by W. Kaelin [21], a loss of
function in one molecule is often correlated with a gaintial, have a unique function in the pathogen, be present
only in the pathogen, and be able to be inhibited by a of function in another. The disruption of oncogenic com-
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plexes is another difficult problem for anticancer drug Expected error 
design. For example, a chromosomal translocation in
0.642  0.00852e
B
7.88  0.687  0.00223e
B
6.16e(2)(atom/refl).core binding factor  causes the formation of a novel
chimeric protein that sequesters necessary transcrip-
Temperature factors of atoms in the region of interesttion factor subunits [22]. Despite the difficulty of design-
should be no greater than the average temperature fac-ing a small molecule to disrupt an unwanted protein
tor for the molecule. High temperature factors can reflectassociation, the specific interface between the fusion
disorder due to motion of the residue or ligand or aprotein and the transcription factor does provide a target
general indication of error, adding to the inaccuracy ofthat can be exploited. Finally, malignancy often alters
atomic positions. In a study reported by Carson et al.the target from its normal behavior, leading to interest
[26], the temperature factor was the most highly corre-in the design of specificity for the malignant state.
lated determinant of R factor. Finally, the molecule
should be refined to be consistent with all rules of ste-
reochemical “correctness” known from small moleculeEvaluating a Structure for Structure-Based
Drug Design structures; deviations from ideal bond lengths should
be no greater than 0.015 A˚ or 3 for bond angles. PlanarOnce a target has been identified, it is necessary to
obtain accurate structural information. There are three atoms should be no more than 0.015 A˚ out of the plane,
and there should be no incorrect chiral centers. Finally,primary methods for structure determination that are
useful for drug design: X-ray crystallography, NMR, and at least 90% of the backbone  and  angles should fall
into the most favored regions of the Ramachandran plot.homology modeling. The evaluation of structures from
each method will be discussed. The PDB header record lists these statistics, and they
should be evaluated before drug design attempts con-Crystal structures are the most common source of
structural information for drug design, since structures tinue. The results of a structure evaluation program,
PROCHECK [27], are also available from the PDB anddetermined to high resolution may be available, and the
method is useful for proteins that range in size from a provide additional detail.
Structures determined by nuclear magnetic reso-few amino acids to 998 kDa [23]. Another advantage
of crystallography is that ordered water molecules are nance, using a concentrated protein or nucleic acid in
solution, are also valuable sources for drug design.visible in the experimental data and are often useful in
drug lead design. A crystal structure should be evalu- Since the target is in solution, it is sometimes possible
to interpret the dynamics of the target from the dataated for the resolution of the diffracted amplitudes (often
simply called resolution); reliability, or R factors; coordi- [28]. Ensembles of structures are deposited in the PDB,
all of which satisfy the distance restraints from the ex-nate error; temperature factors; and chemical “correct-
ness.” Typically, crystal structures determined with data perimental data and show reasonable stereochemical
parameters. There is no analogous reliability factor asextending to beyond 2.5 A˚ are acceptable for drug de-
sign purposes since they have a high data to parameter in crystallography, but the quality of the structure is
often measured by the rms deviations of the coordinatesratio, and the placement of residues in the electron den-
sity map is unambiguous. The R factor and Rfree reported of the members of the ensemble from the average struc-
ture (often divided into main chain and side positions)for a model are measures of the correlation between
the model and experimental data. The Rfree value should and overall stereochemical soundness, including van
der Waals violations, phi/psi conformational angle anal-be below 28% and ideally below 25%, and the R factor
should be well below 25% in order to use the structure in ysis, side chain torsion angle analysis, bond lengths,
bond angles, and planarity. NMR data are often col-drug design. If the only structure available for a particular
target does not meet the resolution or R factor criteria, lected by measuring nuclear Overhauser effect (NOE)
peaks between resonant nuclei that are a distance ofdrug design projects can still be considered, but the
results should be judged carefully. less than 5 A˚ apart in the tertiary structure. Another
important statistic for evaluating NMR-derived struc-Low coordinate error in a crystal structure is crucial
since van der Waals interactions modulate with the sixth tures is the number of unfulfilled NOE restraints, other-
wise called violations. NOE violations are crosspeakspower of the distance between atoms, and directional
bonds, such as hydrogen bonds and electrostatic inter- between resonant nuclei that appear in the experimental
data but are unexplained in the model. A final evaluationactions, have a narrow tolerance for both the angle and
distance (approximately 0.2 A˚). Coordinate error can be statistic is the total number of NOE restraints per resi-
due, or data:parameter ratio.measured in many different ways, but two significant
methods are the Luzzati method [24], based on averag- In a survey of 97 deposited NMR structures in the
PDB [29], Doreleijers et al. found that the average struc-ing coordinate error as a function of R factors that vary
with resolution, and methods in which expected errors ture had 11.3 restraints per residue and 61 NOE viola-
tions. The precision of the structures, as defined by theare calculated based on the temperature factor, or B
factor, of an atom and the atom:reflection ratio [25]. The circular variance of the backbone dihedral angles, is
clearly correlated with the number of restraints per resi-Luzzati coordinate error is often reported in coordinates
deposited with the Protein Data Bank (PDB) and should due. The number of residues in the most favored regions
of the Ramachandran plot is also correlated with thebe in the range of 0.2–0.3 A˚. For further accuracy in error
determination, the B factor (B) and atom:reflection ratio number of restraints per residue and a low number of
NOE violations. The programs PROCHECK-NMR [30](atom/refl) can be included, as in the Stroud and Fauman
method: and WHAT IF [31], the results of which are available from
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the PDB, provide additional structure-based details for torial chemistry, in which thousands of compounds are
tested for biochemical effects.evaluating NMR structures. One other note to consider
is that the average structure from the ensemble may or The computer-aided methods can be further classi-
fied into at least three categories: inspection, virtualmay not actually exist; therefore, one of the members
of the ensemble or the entire ensemble itself may be a screening, and de novo generation. In the first category,
inspection, known molecules that bind the site, suchbetter target choice.
If no experimentally determined structure is available, as substrates or cofactors in the case of enzymes, or
peptides in the case of protein:protein or protein:nucleica homology model can be used for drug design [32–34].
To evaluate a homology model, SWISS-MODEL [35] out- acid interactions, are modified to become inhibitors
based on maximizing complementary interactions in theputs a confidence factor per residue that reflects the
amount of structural information used to create that target site [1, 3, 41, 42]. In virtual screening, databases
of available small molecules are docked into the regionportion of the model. A higher confidence number re-
flects a lower number of templates and therefore a de- of interest in silico and scored based on predicted inter-
actions with the site. Finally, for de novo generationcreased accuracy. All other methods for judging protein
structures, such as stereochemical soundness (bond small fragments of molecules, such as benzene rings,
carbonyl groups, amino groups, etc., are positioned inlengths, bond angles, planarity, and packing) and resi-
dues in the most favored regions of the Ramachandran the site, scored, and linked in silico. The final com-
pounds, created in silico from the linked fragments, thenplot, apply to analyzing a homology model as well as
to experimentally derived models. must be synthesized in the laboratory. There is some
overlap between the virtual screening and de novo gen-Using the structural information obtained through the
above techniques, the structure is then prepared for eration classifications. Some programs, for example,
LUDI, which is usually used to dock fragments of com-drug design programs by first adding hydrogen atoms,
usually absent in crystal structures determined with data pounds, are also capable of docking and scoring entire
compounds. The programs are classified in Table 1 ac-at a resolution lower than 1.0 A˚. The protonation and
tautomeric states of residues as well as the state of cording to their primary use.
There are many excellent drug design software meth-histidine residues (, 	, or both nitrogens protonated)
should be assigned. Small molecules, such as ions and ods available capable of either virtual screening or de
novo generation. This review will focus on a few of thewater molecules, can be included during the lead gener-
ation phase in cases where they play structural roles major points necessary to decide on a particular route
for lead generation. Extensive reviews of the softwarethat are crucial for the conformation of the target, other-
wise they are usually removed to allow any potential are available [11, 12, 14, 15, 43] and are highly recom-
mended for further reading.lead to occupy their positions.
Questions that are pivotal in deciding on a method
for lead generation are as follows: (1) are moleculesIdentification of the Target Site
available which can be modified to be inhibitors, (2) isStructure-based design begins with the identification of
there a means for synthesizing novel molecules, and (3)a potential ligand binding site on the target molecule.
what is the degree of accuracy required at a particularIdeally, the target site is a pocket or protuberance with
stage of the design process versus the time needed fora variety of potential hydrogen bond donors and ac-
the calculation? Factors such as the inclusion of proteinceptors, hydrophobic characteristics, and sizes of mo-
or ligand flexibility and the effects of solvent increaselecular surfaces. The ligand binding site can be the ac-
the time needed for the calculation but also increasetive site, as in an enzyme, an assembly site with another
the predictive value. Each of these questions will bemacromolecule, or a communication site necessary in
discussed with reference to available drug design algo-the mechanism of the molecule. In addition to the well-
rithms.accepted protein target sites, RNA secondary structural
Modifying an Initial Compoundelements can provide excellent target sites since they
Substrates and cofactors for many proteins have beenare species specific, bind ligands, and can be specific
modified to become excellent inhibitors [1, 3, 41, 42, 44,for a disease state [36, 37]. Target sites for protein-
45] (see Figure 2 for an example). Initially, the crystalprotein interactions can be difficult to locate since these
structure is solved in the presence of a substrate, cofac-surfaces are often flat, large, and hydrophobic, but even
tor, or drug lead. Then, modifications to direct the smallthese difficulties can be surmounted [38–40]. Cocrystal-
molecule toward being a potent inhibitor are designedlization studies in which the target macromolecule is
in silico based on the interactions of the molecule withcrystallized with an initial small molecule inhibitor can
the target site. The newly designed compounds are then
be invaluable for the determination of a good target site.
scored for binding using evaluative scoring algorithms
available in virtual screening methods.
Drug Design Methods Docking Available Small Molecules versus De
Once the structure and target site are identified, there Novo Generation
are several paths to developing a good lead based on The main advantage to docking compounds from data-
the structure of the target. These paths can be broadly bases such as the Available Chemicals Database (ACD)
classified as computer aided versus experimental. Com- into the target site is that hit compounds can be pur-
puter-aided methods will be the main focus of this re- chased and tested using biochemical assays. Alterna-
view. An example of an experimental method, by way tively, instead of testing the entire database, a database
can be refined to select molecules with a specific motif.of contrast, is high-throughput screening with combina-
Review
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Table 1. Algorithms for Docking Small Molecules or Fragments against a Target
Flexible Flexible
Program Protein? Ligand? Description Reference
Virtual screening DOCK no yes docks either small molecules or fragments, [46–49]
includes solvent effects
FlexX no yes incremental construction [51]
FlexE yes yes incremental construction; samples ensem- [52]
bles of receptor structures
SLIDE yes yes anchor fragments placed, remainder of [50]
ligand added; backbone flexibility
Flo98 no yes can rapidly dock a large number of ligand [76]
molecules, graphically view results
ADAM no yes fragments aligned based on hydrogen [77]
bonding
Hammerhead no yes genetic algorithms to link tail fragments [78]
to anchor fragments
MCSA-PCR yes yes uses simulated annealing to generate [64]
conformations of target
AUTODOCK yes yes uses averaged interaction energy grid [79]
to account for receptor conformations
and simulated annealing for ligand
conformations
MCDOCK no yes Monte Carlo to sample ligand placement [80]
ProDOCK yes yes Monte Carlo minimization for flexible [81]
ligand, flexible site
ICM yes yes Monte Carlo minimization for protein- [82]
ligand docking
DockVision no no Monte Carlo minimization [83]
De novo generation LUDI no yes docks and scores fragments [54]
of ligands
GRID no yes calculates binding energies for functional [55]
groups
MCSS no yes exhaustive search of binding site for [56]
functional group minima
SMoG no yes knowledge-based scoring function; [58]
molecules built by joining rigid fragments
CONCERTS no yes fills active site with molecular fragments, [57]
links fragments
Legend no yes grows molecule atom by atom [84]
DLD no yes saturates binding site with sp3 carbons, [85]
later linked
GrowMol no yes builds ligands from a library of atom types [86]
GenStar no yes builds ligands from sp3 carbons [87]
GROW no yes constructs a peptide by residue addition [88]
GroupBuild no yes builds ligand from a predefined library of [89]
fragments
HOOK no yes searches database of molecular skeletons [90]
for fit to binding site; hooks two MCSS
functional groups to skeleton
SPROUT no yes generates skeletons that fit site, substi- [91]
tutes atoms into skeleton to give molecule
with correct properties
CAVEAT no yes searches database of small molecules to [92]
connect fragments
Programs such as DOCK [46–49], SLIDE [50], FlexX [51], compounds are currently being incorporated in a version
of LUDI [14, 53]. LUDI [54], GRID [55], MCSS [56], CON-or FlexE [52] and others (see Table 1) dock databases
of compounds and score them according to their inter- CERTS [57], SMoG [58], and others represent examples
of de novo lead generation programs (see Table 1).actions with the site. Novel scaffolds for inhibitors can
be discovered in this way. Time of Calculation versus Predictive Value
In an initial lead generation run, one common goal is toDe novo lead generation can give rise to novel com-
pounds; however, it does require a team member who determine the feasibility of the project and the classes
of possible leads that may result. Most programs cancan actually synthesize the intended product in the labo-
ratory. Fragments of molecules, usually small functional be run in a “basic” mode which allows this determina-
tion. For instance, DOCK [46–49] can position and scoregroups, are docked into the site, scored, and linked
together. Ideally, the fragments can more fully explore all of the compounds in the ACD quite quickly when run
with a single rigid target, rigid ligands, and no solventthe binding site than a predefined compound. Means
for predicting the synthetic accessibility of the novel modeling. However, the predictive value of these pro-
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Figure 2. Inhibitors for Thymidylate Synthase
Were Designed Based on Modifications of the
Cofactor 5,10-Methylene Tetrahydrofolate
Several potent inhibitors are shown: (B)
CB3717, (C) OSI 1843U89, and (D) ZD1694
(Tomudex).
grams can be greatly increased when routines that dicted by molecular dynamics [62], or generated using
rotamers of protein side chains [50, 63]. Using a molecu-model protein and ligand flexibility as well as solvent
lar dynamics simulation to generate multiple proteincontribution are added.
conformations, Carlson et al. have experimentally veri-Protein and Ligand Flexibility. There have been many
fied a dynamic pharmacophore model for HIV-1 integ-reports which emphasize the crucial effects of including
rase [62]. Programs which mimic protein flexibilityprotein and ligand flexibility in the docking and scoring
through the use of ensembles include SLIDE [50], FlexEprocess [15, 43, 59]. Most proteins and most ligands
[52], and MCSA-PCR [64].are quite flexible in solution and may experience a full
Solvent Effects. Solvent plays an important role inensemble of possible conformations. As a result, leads
ligand binding in several ways. In one capacity, orderedgenerated from a single, rigid structure may have dif-
water molecules seen in the structure can be incorpo-fering results in solution than in silico [60]. In order to
rated into the designed ligand, effectively increasingaccount for the landscape of protein and ligand confor-
ligand binding by increasing the entropy of the systemmations, several drug design algorithms incorporate
(releasing the bound water molecule). As an example,protein and/or ligand flexibility. However, modeling mo-
inhibitors for HIV protease [65] incorporate an oxygenlecular flexibility, especially for the target macromole-
atom to substitute for a key water molecule coordinatedcule, drastically increases the compute time required
by residues of the flap region of the active site (seefor the structure-based drug design (SBDD) search.
Figure 4). In a second capacity, ordered water moleculesMany programs that allow protein flexibility incorpo-
can be treated as bound ligands, and contacts withrate information from multiple protein structures. En-
them can be maximized [66]. In a third capacity, thesembles of structures can be experimentally deter-
effect of the solvent can be incorporated into the scoringmined, such as NMR ensembles (see Figure 3) or
scheme for the target:ligand interaction. The steps ofmultiple crystal structures [61], computationally pre-
increased accuracy in modeling the solvent effect during
scoring are as follows: (1) making the assumption that
the molecules are in a vacuum, i.e., no solvent modeling;
(2) using a fixed dielectric constant in estimating electro-
static contributions; (3) explicit solvation models; and
(4) modeling the Born equation. The Born equation cal-
culates the polarization contribution to solvation when
a charge is placed within a spherical solvent cavity.
In general, increased accuracy comes with increased
computational cost.
The correct value for the dielectric constant of the
medium is critical in properly evaluating electrostatic
effects and estimating binding affinity. In the Northwest-
ern University version of DOCK [49], a solvation correc-
tion can be added to the score. Possible approaches
to achieve an exact solution to the solvent problem
include solving the Poisson-Boltzmann equation, often
by using finite differences, or using a free-energy pertur-
bation technique. Three approaches have been used
in practice: a modified Born equation [49] to calculate
solvation energies, an approximation to the electrostatic
desolvation by modeling the first solvation shell at the
binding interface [67], and an implicit model which ac-
counts for desolvation by computationally generating
possible positions of water molecules in the binding
pocket [68].Figure 3. An Ensemble of Six Structures of Dihydrofolate Reductase
Six (out of a total of 24 reported) structures of dihydrofolate reduc-
Drug Lead Evaluationtase bound to trimethoprim (red) and NADPH (orange) (1LUD; [93])
Once a small molecule has been identified as potentiallyare shown. Each member of the ensemble is separately colored,
and hydrogens are omitted for clarity. binding to the target molecule, it must be evaluated
Review
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Figure 4. Nonpeptide HIV Protease Inhibitors
Based on Cyclic Urea Compounds Incorpo-
rate an Oxygen Atom Where a Bound Water
Molecule Was Visualized in X-Ray Structures
Nonpeptide HIV protease inhibitors based on
cyclic urea compounds incorporate an oxy-
gen atom (noted) where a bound water mole-
cule was visualized in X-ray structures.
before proceeding to further stages. It is important to ful, since enzymes are often good drug targets and the
active site provides an excellent ligand binding site forconsider that the ranking assigned by the scoring func-
tion is not always indicative of a true binding constant, drug design. Amprenavir (Agenerase) and nelfinavir (Vira-
cept) [72], developed against HIV protease, were de-since the model of the target:ligand interaction is inher-
ently an approximation. Both the solvent effect and the signed using mainly structure-based methods and are
two of the first drugs to reach the market using SBDD.effects of target and ligand flexibility are usually impre-
cisely described. Usually, several molecules which More recently, zanamivir (Relenza) was developed
against neuraminidase [73], Tomudex was developedscored well during the docking run are evaluated in
further tests since even the top scoring molecule could against thymidylate synthase [44], and imitinab mesylate
(Glivec) inhibits Abl tyrosine kinase [74]. With the devel-fail in vitro assays. Leads are first evaluated visually with
computer graphics and can often be optimized at this opment of structure-based design against difficult drug
targets such as nucleic acids and protein:protein inter-step for increased affinity. Leads are also evaluated for
their likelihood to be orally bioavailable using the “Rule actions, exciting breakthroughs have recently occurred
in the field. Structure-based drug design has revealedof 5” [69], which states that good leads generally have
less than five hydrogen bond donors and less than ten specific, micromolar inhibitors against the HIV-1 RNA
target TAR [36, 37], the IL-2/IL-2R
 receptor interactionhydrogen bond acceptors, a molecular weight less than
500, and a calculated log of the partition coefficient [39], the VEGF/VEGF receptor [40], and Bcl2 [33]. Struc-
ture-based design against the enzyme target AmpC(clogP) less than 5. Rigidifying the lead can also impart
a lower binding constant by decreasing the conforma- -lactamase illustrates the principles of drug design out-
lined in this review and will be discussed in further detailtional entropy in the unbound state to approach the
presumably very low conformational entropy in the in this section.
-lactamases are bacterial enzymes that cause re-bound state. Veber and colleagues [70] state that the
number of rotatable bonds should be less than ten in sistance to -lactam antibiotics such as the com-
monly prescribed drugs penicillin and cephalosporin.order to increase the potential for oral bioavailability.
Other factors, such as chemical and metabolic stability -lactamase is a good drug target because it is unique
to the pathogen, can be inhibited by a small molecule,and the ease of synthesis, can also factor into the deci-
sion to proceed with a particular candidate lead. Finally, and is essential for the pathogen’s resistance to
-lactam antibiotics. The -lactamase enzyme has aleads are brought into the wet lab for biochemical evalu-
ation. serine nucleophile at the active site that cleaves the
-lactam ring of the antibiotic, effectively destroying anyPromising leads reenter the structural determination
process to find the exact binding mode and to evaluate pharmaceutical benefit. -lactamase inhibitors, such as
clavulanic acid, are often coadministered with -lactamany further optimization that becomes evident. A few
examples of designed leads have shown significant dif- antibiotics, but these inhibitors are -lactams them-
selves, causing upregulation of the expression of theferences between predicted and actual binding modes
[71], but in many cases the docked and experimental -lactamase. Novel -lactamase inhibitors that do not
upregulate expression are needed in order to preventconformations are within 2 A˚ rmsd [16].
antibiotic resistance.
The Northwestern University version of DOCK [47, 49]AmpC -Lactamase Case Study
There have been many important successes in struc- was used to screen the ACD against a consensus struc-
ture, a “hot spot” model of AmpC -lactamase. Theture-based drug design.
The discovery of enzyme inhibitors has been success- consensus structure incorporated experimentally and
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Figure 5. Drug Design against AmpC -Lactamase
(A) Ball-and-stick representation of compound 1 (red), discovered with a DOCK screen, bound to AmpC -lactamase.
(B) Compound 1 (space filling) bound to AmpC -lactamase (residues within 7 A˚ are shown with van der Waals surfaces).
computationally derived ligand binding data from 13 found to be essential. The addition of a piperidine ring
to the distal aryl ring increased binding by 2-fold. Finally,AmpC-lactamase structures [75]. The consensus bind-
ing sites for AmpC -lactamase include an amide recog- compound 1 is relatively “drug-like,” according to Lip-
inski’s rules [69], and has sites for future synthetic elabo-nition site, an oxyanion hole, hydroxyl and carboxyl
binding sites, and, finally, four ordered water molecules ration.
In summary, AmpC -lactamase is an excellent drugshown to consistently bind either the enzyme or the
inhibitors. The top 500 scoring molecules from the target with accurate structural information. The North-
western University version of DOCK was used to screenDOCK run were examined graphically for complemen-
tarity, polar interactions, and agreement with the identi- the ACD to find novel inhibitor scaffolds. The top-scoring
compounds were novel and predicted to have comple-fied binding sites. Fifty-six compounds were purchased
and tested with in vitro assays. Three compounds inhibit mentary interactions with the target site, but were shown
to have relatively low binding constants in solution. Fur-with Ki  650 M or better. Compound 1 was shown to
be selective for AmpC -lactamase over other serine ther improvement will be needed before the drug lead
can proceed into future trials. Structural studies of thenucleophile enzymes and was selected for further study.
Powers et al. [66] determined the cocrystal structure selected inhibitor and the enzyme are invaluable in fu-
ture chemical elaboration.of AmpC -lactamase and compound 1 (Figure 5). The
structure was determined to a resolution of 1.94 A˚, with The results of the AmpC -lactamase case study also
exemplify the sort of reasonable expectations oneR factor 17.3% and Rfree 20.7%, coordinate error 0.19 A˚,
average B factor 23 A˚2, and average B factor for com- should have for initial structure-based drug design stud-
ies. One, micromolar inhibitors were discovered throughpound 1, 37 A˚2. The structure is stereochemically cor-
rect, citing an rmsd from ideality for bond lengths  the docking procedure and will serve as lead com-
pounds requiring further modification for increased po-0.009 A˚ and bond angles  1.5. The DOCK-predicted
conformation of compound 1 closely resembles the tency. It is very rare that extremely potent inhibitors
(nM inhibition or better) are discovered during dockingcrystallographically determined conformation of com-
pound 1. In fact, the rmsd for all inhibitor atoms is 1.87 A˚ screens. Two, 56 top-scoring compounds were pur-
chased and tested in vitro after the initial dockingfor one molecule in the asymmetric unit of the crystal
and 1.75 A˚ for the second molecule in the asymmetric screen. Due to approximations in the models of protein
and ligand interactions in the scoring algorithms, theunit. The predicted interactions were also highly corre-
lated with the crystallographically determined interac- docked compounds may be ranked in slightly different
order than their in vitro assays reveal. In fact, some of thetions: of nine hydrogen bonds observed in the crystal
structure, seven were predicted, and of eight hydrogen hits from the docking study may not exhibit successful in
vitro results at all. Structure-based drug design methodsbonds predicted, only one was not observed crystallo-
graphically. increase the chance that a “hit” will be found in the top-
ranked ligands.Compound 1 was tested in microbiology experiments
and found to reduce the minimum inhibitory concentra-
tion (MIC) of ampicillin by 4-fold in -lactamase-positive Promise for the Future
Structure-based drug design is a powerful method, es-bacteria. Analogs of compound 1 were tested to deter-
mine which functional moieties were essential. The car- pecially when used as a tool within an armamentarium,
for discovering new drug leads against important tar-boxylate group, the proton donating ability of the sulfon-
amide, and the atom order of the sulfonamide were gets. After a target and a structure of that target are
Review
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flexibility in computational drug design. Mol. Pharmacol. 57,chosen, new leads can be designed from chemical prin-
213–218.ciples or chosen from a subset of small molecules that
16. Shoichet, B., McGovern, S., Wei, B., and Irwin, J. (2002). Leadscored well when docked in silico against the target.
discovery using molecular docking. Curr. Opin. Chem. Biol. 6,
After a preliminary assessment of bioavailability, the 439–446.
candidate leads continue in an iterative process of reen- 17. Klebe, G., and Bohm, H. (1997). Energetic and entropic factors
determining binding affinity in protein-ligand complexes. J. Re-tering structural determination and reevaluation for opti-
cept. Signal Transduct. Res. 17, 459–473.mization. Focused libraries of synthesized compounds
18. Gallego, J., and Varani, G. (2001). Targeting RNA with small-based on the structure-based lead can create a very
molecule drugs: therapeutic promise and chemical challenges.promising lead which can continue to phase I clinical
Acc. Chem. Res. 34, 836–843.
trials. 19. Afshar, M., Prescott, C., and Varani, G. (1999). Structure-based
As structural genomics, bioinformatics, and computa- and combinatorial search for new RNA-binding drugs. Curr.
Opin. Biotechnol. 10, 59–63.tional power continue to explode with new advances,
20. Hopkins, A., and Groom, C. (2002). The druggable genome. Nat.further successes in structure-based drug design are
Rev. Drug Discov. 1, 727–730.likely to follow. Each year, new targets are being identi-
21. Kaelin, W. (1999). Choosing anticancer drug targets in the post-fied, structures of those targets are being determined genomic era. J. Clin. Invest. 104, 1503–1506.
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